logo-loader

Pressure BioSciences says software upgrade enhances Barocycler 2320EXT instrument

Last updated: 16:51 20 Dec 2017 GMT, First published: 11:51 20 Dec 2017 GMT

1513788809_sareum-test-tubes
The machine is mainly used to prepare samples (tissues, cells, proteins) for analysis

Pressure BioSciences Inc (OTCMKTS:PBIO) says its redesigned software for its pressure-based Barocycler 2320EXTREME instrument will "significantly" expand its uses and appeal in the biopharma market.

The enhancement makes the 2320EXT device one of the few good manufacturing practices (GMP) compliant sample preparation systems available in the worldwide life sciences market today, the company said.

READ - Pressure BioSciences expects BaroFold Inc to have "significant" impact on revenues in 2018

The machine is mainly used to prepare samples (tissues, cells, proteins) for analysis and has been installed in research and manufacturing laboratories worldwide.

"GMP compliance is not only mandated by the U.S. Food and Drug Administration and equivalent regulatory bodies worldwide, it is also widely accepted by the world's biopharmaceutical companies as the best - if not the only - way to bring a new product to market," noted Dr Alexander Lazarev, the vice president of R&D (research and development) at  Pressure BioSciences.

GMP covers all aspects of production, from starting materials to the final released product.

Having GMP-compliant features should allow the Barocycler 2320EXT to be used in multiple departments within the same company, and for multiple applications, said the US-listed firm.

Sample preparation is often complex, time-consuming, and one of the most error-prone steps in research.

READ - Zacks upbeat on Pressure BioSciences' growth potential; targets US$10 a share

It is also a large and growing market, estimated currently at US$6 billion worldwide.

It's been a busy month for Pressure BioSciences.

It has announced the acquisition of all assets of BaroFold Inc, which is expected to enhance revenues and increase its IP (intellectual property) portfolio.

BaroFold, among other assets, has developed PreEMT technology, which improves the quality of manufacturing  biopharma products and decreases manufacturing costs (by as much as US$2-10mln per year per commercial biologic drug), the firm said.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

3 hours, 1 minute ago